Home › Squamous Cell Carcinoma
Squamous Cell Carcinoma clinical trials recruiting in the U.S.
56 studies for Squamous Cell Carcinoma are recruiting participants at sites across the United States.
Cities with the most studies
- Pittsburgh, PA11 studies
- Los Angeles, CA9 studies
- Nashville, TN8 studies
- New York City, NY7 studies
- Boston, MA7 studies
- Houston, TX7 studies
- Durham, NC6 studies
- St. Louis, MO6 studies
- San Diego, CA6 studies
- Chicago, IL5 studies
- Queens, NY4 studies
- Washington, DC4 studies
- Orlando, FL4 studies
- Atlanta, GA4 studies
- Tampa, FL4 studies
- Staten Island, NY3 studies
- Dallas, TX3 studies
- Philadelphia, PA3 studies
- Charleston, SC3 studies
- Baltimore, MD3 studies
- Rochester, NY3 studies
- Arlington, VA3 studies
- Indianapolis, IN3 studies
By state
- California13 studies
- Florida13 studies
- Georgia4 studies
- Illinois5 studies
- Indiana3 studies
- Kentucky3 studies
- Maryland4 studies
- Massachusetts7 studies
- Michigan3 studies
- Minnesota3 studies
- Missouri6 studies
- New Jersey3 studies
- New York15 studies
- North Carolina7 studies
- Ohio4 studies
- Pennsylvania14 studies
- South Carolina4 studies
- Tennessee9 studies
- Texas12 studies
- Virginia6 studies
Recently updated studies
Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT02507141Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07741643Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07631013Evaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07931664Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07741565Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Nov 3, 2026 · NCT04892173Basal Cell Carcinoma Chemoprevention Trial
RecruitingPhase 3Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT05212246Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07901959Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06295731Intratumoral N17350 in Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT07339176T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 2
Ages 18 to 72 · All sexes · Updated Oct 20, 2026 · NCT02133196PDT For Induction Therapy For Head And Neck Cancer
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07214987Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 16, 2026 · NCT07460765Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07869823A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07115043Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 6, 2026 · NCT04429542The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07285044Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06736379Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05027633Effects of Infusion Timing on Treatment Response in Solid Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07630168Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07513389A Study of IDP-001 in Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07602842Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Sep 2, 2026 · NCT04915183From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.